Brief Title
Sham LaserCap vs. LaserCap SD vs. LaserCap HD+
Official Title
Effect of Increasing Fluence on Efficacy of Low Level Laser Therapy for Androgenetic Alopecia, a Randomized Control Trial
Brief Summary
Androgenetic alopecia (AGA) is a prevalent disease, occurring in 80% of Caucasian men and 50% of Caucasian women by age 701. Treatments for AGA are limited, and presently the only FDA-approved medications for AGA are topical minoxidil and oral finasteride1. In addition to medical therapies, FDA-cleared medical devices are now utilized for the treatment of AGA as of 20072. These devices, termed low level laser therapy (LLLT), come in multiple forms including combs, helmets and sports cap wearable devices2. These home-use, wearable devices utilize the ~650 nm wavelength laser light to stimulate the hair follicle mitochondria and thereby promote hair growth, a process termed "photobiomodulation"3. Recent meta-analyses investigating photobiomodulation and LLLT for AGA have noted an increase in fluence or energy delivered per cm is associated with increased hair density3. However, randomized control trials (RCT) with direct comparison of LLLT devices of different fluences has yet to be performed. Accordingly, in the present study we aim to investigate if increasing fluence in LLLT devices is associated with increased hair density by comparing sham LaserCap to LaserCap SD (1.15 J/cm2, low fluence) and LaserCap HD+ (3.93 J/cm2, high fluence) in RCT.
Study Type
Interventional
Primary Outcome
Target area total hair count at 26 weeks via phototrichogram
Secondary Outcome
Target area vellus hair count at 26 weeks via phototrichogram
Condition
Androgenetic Alopecia
Intervention
LaserCap SD
Study Arms / Comparison Groups
Sham LaserCap
Description: Sham device
Publications
* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.
Recruitment Information
Recruitment Status
Device
Estimated Enrollment
50
Start Date
September 2022
Completion Date
August 2024
Primary Completion Date
December 2023
Eligibility Criteria
Inclusion criteria: - 25 years and older - Men and women with AGA, untreated or with 6-month washout of previous treatments - Men: Norwood stage IIa - V - Women: Ludwig I-1 - II-2, or frontal pattern - All patients: Fitzpatrick skin types I to IV Exclusion criteria: - Men: Norwood stage Va, VI, VII - Women: Ludwig stage III, advanced - All patients: Fitzpatrick skin types V, VI - Current use or within the past six month of other treatment for AGA, including topical and oral minoxidil, topical and oral finasteride and dutasteride - Age 0-25 years
Gender
All
Ages
25 Years - N/A
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Contacts
, (520) 694-8888, [email protected]
Administrative Informations
NCT ID
NCT05365360
Organization ID
LLLT Fluence RCT
Responsible Party
Sponsor
Study Sponsor
University of Arizona
Collaborators
Transdermal Cap, Inc.
Study Sponsor
, ,
Verification Date
May 2022